News – BioArctic

The story behind BioArctic’s and AbbVie’s successful collaboration published on The Rhythm of Business

August 19, 2020 - News

For a research company with the ambition to help patients with serious illnesses to a better life, determination, focus and collaboration, is of utmost importance to ...

BioArctic second place for the Allbright Prize 2019

November 27, 2019 - News

BioArctic, for the second year in a row, was named as the second place finalist for the Allbright prize for its work with gender equality. ...

Gunilla Osswald named “Pharmacist of the Year”

September 25, 2019 - News

Sveriges Farmaceuter, a Swedish professional association for pharmacists, has chosen BioArctic’s CEO, Gunilla Osswald, as this year's recipient of the “Pharmacist of the Year” award. This ...

September is World Alzheimer’s Month

September 20, 2019 - News

September is the official world Alzheimer's month, raising awareness for this disease globally. Approximately 50 million people suffer from dementia worldwide, and in Sweden, it afflicts ...

BioArctic shortlisted for the European Lifestars Awards

August 30, 2019 - News

BioArctic is one of the finalists for the European Lifestars Awards in the category ”Deal of the Year (>£500m)” for its strategic collaboration with AbbVie ...

Why is BioArctic unique?

August 20, 2019 - News

BioArctic's CEO, Gunilla Osswald, explains why in an interview with PharmaBoardroom https://pharmaboardroom.com/interviews/gunilla-osswald-ceo-bioarctic-sweden/

BioArctic participates at Dementia Forum X

May 15, 2019 - News

BioArctic’s CEO Gunilla Osswald speaking at the Dementia Forum X at the Royal Palace in Stockholm, participating in a global initiative to fight dementia.

Lars Lannfelt receives the Swedish Alzheimer’s Foundation’s (Alzheimerfondens) Grand Research Prize 2019

January 8, 2019 - News

Lars Lannfelt, Senior Professor of Geriatrics at Uppsala University, receives the Swedish Alzheimer's Foundation’s Grand Research Prize 2019 of SEK 2.5 million. He receives the award ...

Rinkeby School visits BioArctic

November 30, 2018 - News

For the ninth consecutive year, BioArctic invited students and teachers from the Rinkeby School in Stockholm and hosted a visit at the company. The Rinkeby School ...

BioArctic proud of the second place of the Allbright Prize 2018

November 23, 2018 - News

The Allbright prize is presented annually to the Swedish listed company that has made the best progress in the area of gender equality during the past ...

BioArctic highly commended at Lifestars Life Science Awards in London

November 20, 2018 - News

BioArctic is pleased to announce that the company has been recognized with a highly commended accolade in the category EU Capital Market Transaction of the Year ...

September – the World Alzheimer’s Month

September 20, 2018 - News

Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2018 marks the seventh ...

BioArctic’s CEO Gunilla Osswald was elected member into the Royal Swedish Academy of Engineering Sciences, IVA

June 5, 2018 - News

At the most recent Assembly of the Academy seven individuals were elected members into the Royal Swedish Academy of Engineering Sciences. Gunilla Osswald was elected member ...

April – the Month of Parkinson’s Disease Awareness

April 11, 2018 - News

April 11 is the World Parkinson’s Disease Day and marks the birthday of Dr. J Parkinson who first described the disease in “An Essay on the ...

BioArctic to present pre-clinical data at the International Conference on Alzheimer’s disease and Parkinson’s disease, ADPD

March 8, 2018 - News

BioArctic will participate at the AAT-AD/PD Focus Meeting (Advances in Alzheimer Therapy - Alzheimer's Disease/Parkinson's Disease) on March 15-18, 2018 in Turin, Italy. At the conference ...

BioArctic receives additional grant from Vinnova for a collaborative research project concerning antibody-based PET imaging for Alzheimer´s disease

November 21, 2017 - News

The grant of SEK 150, 000 from Vinnova will be used for a development of a regulatory plan and to evaluate the commercial potential of the ...

BioArctic strengthens Regulatory Affairs, employs Nora Sjödin

September 25, 2017 - News

BioArctic AB has employed Nora Sjödin as responsible for Regulatory Affairs. She takes up her duties in the company today.

September – the World Alzheimer’s Month

September 16, 2017 - News

Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2017 marks the sixth ...

BioArctic AB: Extraordinary General Meeting on September 4, 2017

September 5, 2017 - News

Election of new board member and new Chairman of the Board: The General Meeting resolved to appoint Eugen Steiner to new board member for the period ...

BioArctic to present poster and participate in round table discussion at international conference on Parkinson’s disease

August 29, 2017 - News

BioArctic will participate at the scientific meeting “20 years of alpha-synuclein in Parkinson’s Disease and related synucleinopathies: from the bedside to the bench and back to ...

Jan Mattsson employed as CFO

August 14, 2017 - News

Effective August 1, Jan Mattsson is employed by BioArctic as CFO. He has been working as CFO in the company as a consultant since February 2017.

BioArctic receives a grant from Vinnova / Medtech4Health for its quality management system work

April 4, 2017 - News

BioArctic has received a grant of 200 000 SEK from Vinnova (Sweden’s Innovation Agency) and Medtech4Health for the company’s quality management system work. The grant is ...

BioArctic to present two posters at the International Conference on Alzheimer’s and Parkinson’s Diseases

March 21, 2017 - News

BioArctic will participate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. The conference is focusing on mechanisms, clinical strategies, and promising ...

BioArctic receives a grant of half a million SEK from Vinnova for a collaborative research project concerning commercial potential of antibody-based PET imaging

March 16, 2017 - News

BioArctic is developing disease modifying treatment for Alzheimer’s disease. One major challenge is the limitations of biomarkers reflecting disease pathology, stage and severity. Thus, there is ...

Granted patent in the US for BAN2401 Backup drug candidate for Alzheimer’s disease which further strengthens BioArctic’s IP position

March 15, 2017 - News

On February 21, 2017, the US Patent Office granted BioArctic a patent (Patent No. US 9, 573, 994 B2) for the company’s antibody BAN2401 Backup for ...

Uppsala University and BioArctic receive a MSEK 5 grant

November 28, 2016 - News

Uppsala University and BioArctic have received a MSEK 5 grant from Vinnova for a collaborative research project concerning reduced costs and improved safety in immunotherapy for ...

Horizon 2020: BioArctic’s Spinal Cord Injury Project in focus at Game Plan Europe 2016

November 22, 2016 - News

Halfway through the world's largest research and innovation program, Horizon 2020, around 400 Swedish organizations have been granted over EUR 550 million in project funding to ...

Update from the Annual General Meeting 2016

August 24, 2016 - News

The annual general meeting in BioArctic Neuroscience AB was held on June 22, 2016.

US patent on Parkinson’s disease granted

April 19, 2016 - News

BioArctic’s patent application encompassing treatment of Parkinson’s disease was granted in US 2016-04-19. The patent (US 9, 315, 569) covers treatment of Parkinson’s disease with an ...

Antibody-based PET imaging of amyloid beta protofibrils in the Alzheimer brain – New findings from Uppsala University in collaboration with BioArctic

March 15, 2016 - News

This is the first time an antibody fragment has been successfully used for PET imaging of a target in the brain. The big advantage with antibodies ...

Innovative Alzheimer therapy: A new license agreement between BioArctic and Eisai on back-up program to BAN2401

September 28, 2015 - News

BioArctic Neuroscience AB announces today that a new license agreement has been signed between BioArctic and the Japanese pharmaceutical company Eisai Co., Ltd.

BioArctic Receives Extended Funding from VINNOVA

September 1, 2015 - News

In August 2015, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted extended ...

BioArctic Neuroscience Parkinson’s disease program receives grant from EU

September 1, 2015 - News

The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for ...

BioArctic Neuroscience Parkinson’s disease program receives grant from VINNOVA

June 15, 2015 - News

The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for ...

BioArctic Neuroscience has been nominated to SwedenBIO Award

June 3, 2015 - News

BioArctic Neuroscience has been nominated to SwedenBIO Award 2015. Each year SwedenBIO Award is awarded to a company that serves as a role model in the ...

Innovative Alzheimer therapy: A new Research Agreement between BioArctic and Eisai initiated

May 19, 2015 - News

BioArctic Neuroscience AB announces today that a new research agreement has been initiated between BioArctic and the Japanese pharmaceutical company Eisai. The research will lead to ...

2nd US patent granted on therapeutic antibodies for Parkinson’s disease

April 2, 2015 - News

On March 3rd 2015, the US patent office granted BioArctic a US patent (US 8, 968, 734 B2) covering therapeutic and diagnostic antibodies for Parkinson’s ...

BioArctic Neuroscience receives major grant from EU

December 19, 2014 - News

The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel treatment for complete spinal cord injury. This project has received funding (6.4 M€) from the ...

2nd US patent granted for therapeutic antibodies for Parkinson’s disease

December 1, 2014 - News

On October 14th 2014 the US patent office granted BioArctic a 2nd US patent (US 8859501) covering therapeutic antibodies for Parkinson’s disease.

BioArctic Neuroscience receives grant from VINNOVA

September 1, 2014 - News

In September 2014, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted up ...

US patent granted on therapeutic antibodies for Parkinson’s disease

August 19, 2014 - News

The US patent office has granted BioArctic a US patent (US 8809506) covering therapeutic and diagnostic antibodies for Parkinson’s disease and Dementia with Lewy Bodies. ...

BioArctic´s new facilities inaugurated

May 5, 2014 - News

Last week, on April 28, BioArctic´s new offices and labs were inaugurated by Ewa Björling, Minister for Trade, Ministry for Foreign Affairs.

Biogen Idec invests together with Eisai in BioArctic´s antibody BAN2401 for treatment of Alzheimer´s disease

March 5, 2014 - News

AGREEMENT TO ENHANCE R&D CAPABILITIES AIMED AT CREATING NEW THERAPIES TO SUPPRESS ALZHEIMER’S DISEASE PROGRESSION

US patent issued for protofibril-binding antibodies for treatment and diagnostics of Parkinson’s Disease, Dementia with Lewy Bodies and other Alpha-Synucleinopathies

January 21, 2014 - News

The US patent office has granted a BioArctic patent for protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's Disease, Dementia with Lewy ...